Evaluation of Fixed Intrathecal Bupivacaine Infusion Doses in the Oncologic Population
ConclusionsFor oncological patients, our data and experience support the initiation of intrathecal bupivacaine at the following doses: 5 mg/day for catheter tips in the cervical spine, 8 mg/day for catheter tips at T1 –4, and 10 mg/day for catheter tips at T5–8. Given the higher likelihood of adverse effects in catheters at T9‐12 and the lumbar spine, we start at 8 mg/day with close follow‐up of the patient. Initiating these doses allow our patients to safely reach adequate analgesia faster, with a shorte r hospitalization and quicker return to anti‐cancer therapy.
Source: Neuromodulation: Technology at the Neural Interface - Category: Biotechnology Authors: Grant H. Chen,
Matthew A. Spiegel,
Yan C. Magram,
Ehtesham Baig,
Keith Clement,
Ilya Laufer,
Amitabh Gulati Tags: Clinical Research Source Type: research
More News: Anesthesia | Anesthesiology | Back Pain | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Therapy | Cervical Cancer | Grants | Morphine | Neurology | Oral Cancer | Pain | Study